References

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

10.1158/1078-0432.ccr-18-4070 · 2019 · External reference

Gastrointestinal stromal tumors: who should get imatinib and for how long?

10.1016/j.yasu.2014.05.014 · 2014 · External reference

Unresolved reference

External reference

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

10.1126/science.1164368 · 2008 · External reference

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

10.1038/nm.2344 · 2011 · External reference

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

10.1038/ng.3398 · 2015 · External reference

Genomic analyses identify molecular subtypes of pancreatic cancer

10.1038/nature16965 · 2016 · External reference

Molecular genetics of pancreatic intraepithelial neoplasia

10.1007/s00534-006-1166-5 · 2007 · External reference

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

10.1158/1078-0432.ccr-17-2994 · 2018 · External reference

Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer

10.1158/1078-0432.ccr-19-1467 · 2020 · External reference

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

10.1158/2159-8290.cd-18-0349 · 2018 · External reference

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

10.1158/1078-0432.ccr-15-0426 · 2015 · External reference

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

10.1158/1078-0432.ccr-18-0531 · 2018 · External reference

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

10.1001/jamaoncol.2017.3420 · 2018 · External reference

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

10.1101/cshperspect.a031435 · 2018 · External reference

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

10.1200/jco.2008.18.9514 · 2009 · External reference

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

10.1158/1078-0432.ccr-14-1814 · 2015 · External reference

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation

10.1200/jco.2022.40.4_suppl.519 · 2022 · External reference

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

10.1056/nejmoa2605555 · 2026 · External reference

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

10.1053/j.gastro.2019.02.037 · 2019 · External reference

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers

10.1200/jco.2022.40.16_suppl.105 · 2022 · External reference

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

10.1016/s1470-2045(19)30691-6 · 2020 · External reference

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

10.1200/po.20.00494 · 2021 · External reference

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

10.1056/nejmoa1011923 · 2011 · External reference

Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer

2014 · External reference

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

10.1200/jco.2014.56.2728 · 2015 · External reference

Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)

2014 · External reference

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

10.1056/nejmoa1903387 · 2019 · External reference

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

10.1200/jco.19.02931 · 2020 · External reference

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

10.1053/j.gastro.2021.01.220 · 2021 · External reference

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

10.1158/2159-8290.cd-18-0275 · 2018 · External reference

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis

10.1200/jco.20.03238 · 2021 · External reference

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

10.1200/jco.20.00590 · 2020 · External reference

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

10.1038/nm.4123 · 2016 · External reference

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

10.1038/s41416-019-0683-3 · 2020 · External reference

Hepatocellular carcinoma

10.1038/s41572-020-00240-3 · 2021 · External reference

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine

10.1016/j.jhep.2017.09.016 · 2018 · External reference

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

10.1038/s41575-020-00381-6 · 2021 · External reference

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

10.1053/j.gastro.2017.06.012 · 2017 · External reference

Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma

10.1097/sla.0000000000002889 · 2018 · External reference

Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients

10.1016/j.surg.2019.08.010 · 2019 · External reference

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

10.1053/j.gastro.2015.05.061 · 2015 · External reference

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

10.1038/s43018-022-00357-2 · 2022 · External reference

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

10.1038/ng.3252 · 2015 · External reference

Molecular therapies and precision medicine for hepatocellular carcinoma

10.1038/s41571-018-0073-4 · 2018 · External reference

Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma

10.1016/j.jhep.2017.08.013 · 2017 · External reference

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling

10.1002/hep.20375 · 2004 · External reference

Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma

10.1002/hep.24813 · 2012 · External reference

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

10.1158/0008-5472.can-09-1089 · 2009 · External reference

Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

10.1016/j.cell.2017.05.046 · 2017 · External reference

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

10.1200/jco.2012.44.5643 · 2013 · External reference

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma

10.1093/jnci/dji315 · 2005 · External reference

Sorafenib in advanced hepatocellular carcinoma

10.1056/nejmoa0708857 · 2008 · External reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

10.1016/s1470-2045(08)70285-7 · 2009 · External reference

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

10.1016/s0140-6736(18)30207-1 · 2018 · External reference

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

10.1056/nejmoa1915745 · 2020 · External reference

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

10.1056/evidoa2100070 · 2022 · External reference

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

10.1016/s1470-2045(15)00198-9 · 2015 · External reference

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

10.2217/fon-2020-0162 · 2020 · External reference

10.1158/1538-7445.am2023-ct003

10.1158/1538-7445.am2023-ct003 · External reference

Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

10.1016/j.jvir.2018.12.607 · 2019 · External reference

1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation

10.1016/j.annonc.2020.08.1133 · 2020 · External reference

A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2

10.1093/annonc/mdz155.216 · 2019 · External reference

Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity

10.1038/s43018-021-00234-4 · 2021 · External reference

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

10.1016/s2468-1253(21)00385-x · 2022 · External reference

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

10.1016/s2468-1253(21)00427-1 · 2022 · External reference

Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study

2022 · External reference

Biliary tract cancer

10.1016/s0140-6736(21)00153-7 · 2021 · External reference

Genomic spectra of biliary tract cancer

10.1038/ng.3375 · 2015 · External reference

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

10.1634/theoncologist.2011-0386 · 2012 · External reference

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma

10.18632/oncotarget.15602 · 2017 · External reference

Precision Medicine in Biliary Tract Cancer

10.1200/jco.21.02576 · 2022 · External reference

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

10.1053/j.gastro.2011.12.005 · 2012 · External reference

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes

10.1053/j.gastro.2013.01.001 · 2013 · External reference

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles

10.1016/j.celrep.2017.06.008 · 2017 · External reference

Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies

10.1002/cncr.11699 · 2003 · External reference

Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models

10.1016/j.jamcollsurg.2016.05.019 · 2016 · External reference

Past, Present, and Future Management of Localized Biliary Tract Malignancies

10.1016/j.soc.2022.07.007 · 2023 · External reference

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

10.1056/nejmoa0908721 · 2010 · External reference

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers

10.1200/jco.2023.41.4_suppl.lba490 · 2023 · External reference

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

10.1200/jco.2022.40.4_suppl.378 · 2022 · External reference

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

10.1200/jco.18.00050 · 2019 · External reference

Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

10.1002/bjs.10776 · 2018 · External reference

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

10.1016/s1470-2045(18)30915-x · 2019 · External reference

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma

10.1245/s10434-023-13809-5 · 2023 · External reference

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

10.1158/1078-0432.ccr-14-3212 · 2016 · External reference

Molecular targeted therapies: Ready for "prime time" in biliary tract cancer

10.1016/j.jhep.2020.03.007 · 2020 · External reference

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

10.1093/annonc/mdt419 · 2014 · External reference

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

10.1016/s1470-2045(20)30109-1 · 2020 · External reference

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

10.1056/nejmoa2206834 · 2023 · External reference

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

10.1016/s2468-1253(21)00196-5 · 2021 · External reference

Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

10.1200/jco.2022.40.4_suppl.427 · 2022 · External reference

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma

10.1158/2159-8290.cd-19-0182 · 2019 · External reference

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

10.1158/2159-8290.cd-21-0697 · 2022 · External reference

Cholangiocarcinoma - novel biological insights and therapeutic strategies

10.1038/s41571-023-00770-1 · 2023 · External reference

New Horizons for Precision Medicine in Biliary Tract Cancers

10.1158/2159-8290.cd-17-0245 · 2017 · External reference

Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review

10.21037/jgo.2019.03.10 · 2019 · External reference

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

10.1016/s1470-2045(20)30157-1 · 2020 · External reference

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)

10.1016/s2468-1253(22)00335-1 · 2023 · External reference

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

10.1016/s1470-2045(21)00336-3 · 2021 · External reference

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

10.1016/s1470-2045(22)00621-0 · 2022 · External reference

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

10.1016/s1470-2045(23)00242-5 · 2023 · External reference

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

2023 · External reference

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)

10.1200/jco.2022.40.16_suppl.4006 · 2022 · External reference

Precision Oncology Targets in Biliary Tract Cancer

10.3390/cancers15072105 · 2023 · External reference

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

10.1038/s41698-021-00206-y · 2021 · External reference

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

10.1056/nejmoa1714448 · 2018 · External reference

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

10.1056/nejmoa1502309 · 2015 · External reference

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

10.1016/s1470-2045(20)30321-1 · 2020 · External reference

Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study

10.1200/jco.2022.40.16_suppl.3008 · 2022 · External reference

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers

10.1002/ijc.33230 · 2021 · External reference

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma

2023 · External reference

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

10.1158/2159-8290.cd-16-1000 · 2017 · External reference

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

10.1126/science.aan6733 · 2017 · External reference

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

10.1016/j.annonc.2022.05.519 · 2022 · External reference

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

10.1016/s1470-2045(20)30445-9 · 2020 · External reference

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

10.1002/ijc.33013 · 2020 · External reference

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

10.1016/s2468-1253(22)00043-7 · 2022 · External reference

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

10.1056/evidoa2200015 · 2022 · External reference

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)00727-4 · 2023 · External reference